Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493833 | 0.86 | SIGMAR1 (0.54) | SIGMAR1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL22493455 | 0.85 | SIGMAR1 (0.46) | SIGMAR1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL23541650 | 0.81 | MEN1 (0.49) | SIGMAR1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL22481135 | 0.78 | ADRB2 (0.54) | ADRB2ADRB3 | |
| SCHEMBL22480918 | 0.74 | MEN1 (0.52) | SIGMAR1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL22493445 | 0.74 | SIGMAR1 (0.49) | SIGMAR1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL22493353 | 0.73 | HTT (0.56) | SIGMAR1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4019777 | 0.72 | SIGMAR1 (0.84) | SIGMAR1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL3621767 | 0.72 | SIGMAR1 (0.84) | SIGMAR1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL19505478 | 0.72 | SIGMAR1 (0.84) | SIGMAR1MEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225021-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2020198466-A9 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020198466-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |